|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DUSP12 |
Gene summary for DUSP12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DUSP12 | Gene ID | 11266 |
| Gene name | dual specificity phosphatase 12 | |
| Gene Alias | DUSP1 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9UNI6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11266 | DUSP12 | P22T-E | Human | Esophagus | ESCC | 1.18e-14 | 3.70e-01 | 0.1236 |
| 11266 | DUSP12 | P23T-E | Human | Esophagus | ESCC | 2.54e-18 | 4.23e-01 | 0.108 |
| 11266 | DUSP12 | P24T-E | Human | Esophagus | ESCC | 9.86e-15 | 3.20e-01 | 0.1287 |
| 11266 | DUSP12 | P26T-E | Human | Esophagus | ESCC | 3.18e-25 | 4.62e-01 | 0.1276 |
| 11266 | DUSP12 | P27T-E | Human | Esophagus | ESCC | 7.91e-12 | 2.61e-01 | 0.1055 |
| 11266 | DUSP12 | P28T-E | Human | Esophagus | ESCC | 3.75e-27 | 5.64e-01 | 0.1149 |
| 11266 | DUSP12 | P30T-E | Human | Esophagus | ESCC | 6.51e-27 | 7.87e-01 | 0.137 |
| 11266 | DUSP12 | P31T-E | Human | Esophagus | ESCC | 1.30e-15 | 3.86e-01 | 0.1251 |
| 11266 | DUSP12 | P32T-E | Human | Esophagus | ESCC | 5.21e-26 | 6.22e-01 | 0.1666 |
| 11266 | DUSP12 | P36T-E | Human | Esophagus | ESCC | 1.64e-18 | 5.94e-01 | 0.1187 |
| 11266 | DUSP12 | P37T-E | Human | Esophagus | ESCC | 1.41e-11 | 2.33e-01 | 0.1371 |
| 11266 | DUSP12 | P38T-E | Human | Esophagus | ESCC | 3.85e-03 | 1.31e-01 | 0.127 |
| 11266 | DUSP12 | P39T-E | Human | Esophagus | ESCC | 2.79e-08 | 2.08e-01 | 0.0894 |
| 11266 | DUSP12 | P40T-E | Human | Esophagus | ESCC | 8.80e-05 | 2.52e-01 | 0.109 |
| 11266 | DUSP12 | P42T-E | Human | Esophagus | ESCC | 3.25e-18 | 2.98e-01 | 0.1175 |
| 11266 | DUSP12 | P44T-E | Human | Esophagus | ESCC | 3.15e-02 | 1.66e-01 | 0.1096 |
| 11266 | DUSP12 | P47T-E | Human | Esophagus | ESCC | 5.01e-14 | 2.26e-01 | 0.1067 |
| 11266 | DUSP12 | P48T-E | Human | Esophagus | ESCC | 3.21e-11 | 2.24e-01 | 0.0959 |
| 11266 | DUSP12 | P49T-E | Human | Esophagus | ESCC | 2.25e-11 | 1.02e+00 | 0.1768 |
| 11266 | DUSP12 | P52T-E | Human | Esophagus | ESCC | 2.70e-20 | 5.25e-01 | 0.1555 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
| GO:00059969 | Esophagus | ESCC | monosaccharide metabolic process | 159/8552 | 257/18723 | 1.11e-07 | 1.81e-06 | 159 |
| GO:00193189 | Esophagus | ESCC | hexose metabolic process | 147/8552 | 237/18723 | 2.63e-07 | 3.94e-06 | 147 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:00060069 | Esophagus | ESCC | glucose metabolic process | 119/8552 | 196/18723 | 1.51e-05 | 1.36e-04 | 119 |
| GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
| GO:00620129 | Esophagus | ESCC | regulation of small molecule metabolic process | 184/8552 | 334/18723 | 3.11e-04 | 1.85e-03 | 184 |
| GO:00109065 | Esophagus | ESCC | regulation of glucose metabolic process | 71/8552 | 119/18723 | 1.46e-03 | 6.92e-03 | 71 |
| GO:00061096 | Esophagus | ESCC | regulation of carbohydrate metabolic process | 101/8552 | 178/18723 | 1.89e-03 | 8.52e-03 | 101 |
| GO:00106755 | Esophagus | ESCC | regulation of cellular carbohydrate metabolic process | 83/8552 | 146/18723 | 4.24e-03 | 1.69e-02 | 83 |
| GO:000599621 | Liver | HCC | monosaccharide metabolic process | 167/7958 | 257/18723 | 2.31e-13 | 1.25e-11 | 167 |
| GO:001931821 | Liver | HCC | hexose metabolic process | 155/7958 | 237/18723 | 7.63e-13 | 3.90e-11 | 155 |
| GO:000600621 | Liver | HCC | glucose metabolic process | 128/7958 | 196/18723 | 8.60e-11 | 3.06e-09 | 128 |
| GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
| GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
| GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
| GO:000610921 | Liver | HCC | regulation of carbohydrate metabolic process | 109/7958 | 178/18723 | 3.36e-07 | 5.78e-06 | 109 |
| GO:00109062 | Liver | HCC | regulation of glucose metabolic process | 76/7958 | 119/18723 | 2.03e-06 | 2.79e-05 | 76 |
| GO:00106752 | Liver | HCC | regulation of cellular carbohydrate metabolic process | 88/7958 | 146/18723 | 1.08e-05 | 1.24e-04 | 88 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DUSP12 | SNV | Missense_Mutation | rs747507283 | c.548N>A | p.Arg183His | p.R183H | Q9UNI6 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| DUSP12 | SNV | Missense_Mutation | c.545A>G | p.Tyr182Cys | p.Y182C | Q9UNI6 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DUSP12 | SNV | Missense_Mutation | novel | c.468N>C | p.Glu156Asp | p.E156D | Q9UNI6 | protein_coding | tolerated(0.2) | possibly_damaging(0.725) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| DUSP12 | SNV | Missense_Mutation | c.71N>T | p.Ala24Val | p.A24V | Q9UNI6 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DUSP12 | SNV | Missense_Mutation | c.998T>C | p.Leu333Ser | p.L333S | Q9UNI6 | protein_coding | tolerated(0.21) | benign(0.025) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| DUSP12 | SNV | Missense_Mutation | rs778635807 | c.547N>T | p.Arg183Cys | p.R183C | Q9UNI6 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| DUSP12 | SNV | Missense_Mutation | novel | c.78N>T | p.Gln26His | p.Q26H | Q9UNI6 | protein_coding | tolerated_low_confidence(0.31) | benign(0) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DUSP12 | SNV | Missense_Mutation | novel | c.753N>T | p.Met251Ile | p.M251I | Q9UNI6 | protein_coding | tolerated(0.62) | benign(0) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DUSP12 | SNV | Missense_Mutation | c.746A>G | p.Lys249Arg | p.K249R | Q9UNI6 | protein_coding | tolerated(0.21) | possibly_damaging(0.566) | TCGA-AP-A0LI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD | |
| DUSP12 | SNV | Missense_Mutation | novel | c.143N>C | p.Leu48Pro | p.L48P | Q9UNI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |